Worldwide, the novel coronavirus has killed at least 1,388,590 people since the outbreak emerged in China last december and at least 58 million cases have been registered.
The United States is the worst-affected country with 256,798 deaths from 12,249,198 cases. At least 4,526,513 people have been declared recovered.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) applied for emergency-use authorization from the US Food and Drug Administration on Friday for their experimental coronavirus vaccine. Both companies gained on the news.
The FDA’s vetting process is set to take a few weeks, and vulnerable populations could receive the shot in early 2021.
Approval for a vaccine comes at a critical point for the US economy. The country reported a record 182,832 new COVID-19 cases on Thursday, according to The COVID Tracking Project. Daily deaths came in just below 2,000, and the number of Americans hospitalized with the virus passed 80,000.
Another COVID-19 vaccine also appears highly effective in preventing illness following exposure to the virus that causes the disease.
The biotech company Moderna Inc. (NASDAQ: MRNA) said last week that its experimental vaccine was 94.5% effective in preventing disease, according to an analysis of its clinical trial.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” Stéphane Bancel, chief executive officer of Moderna, said in a statement.
The news comes a week after Pfizer and BioNTech said their vaccine was more than 90% effective.
Countries worldwide, as well as international organizations, were working out plans for global distribution of these vaccines and potentially others still being developed.
Halberd Corp. (OTC:HALB) has the potential for considerable gain, whether it’s because they’re developing a treatment or their products are in greater need amid the outbreak.
In a recent press release, Halberd Corporation announced reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is an improvement to an earlier provisional patent application, “Nasal Spray to Prevent the Transmission of Covid-19 Between Humans.”
Multiple medical articles (1, 2) have shown that intra-nasal ACE2 receptors, which are more prevalent in older adults than children, are thought to be a key factor in adults being infected with Covid-19 at higher rates than children. Recent studies have shown Neuropilin-1, a protein widespread in the body, but occurring primarily on cells in the lungs and nose (3), provides additional binding sites for the Covid-19 spike protein. By blocking ACE2 receptors and Neuropilin-1, it is believed Covid-19 spike proteins can be prevented from attaching to receptors in nasal passages, and reducing the disease’s infectivity (4).
Mr. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “As more becomes known about the Covid-19 virus, the better we are able to configure our treatments to combat the disease. This new intellectual property is a case in point. This second nasal spray configuration, which builds on the initial design, we believe will provide enhanced protection against contracting Covid-19 by preventing access through nasal receptors.”
A COVID-19 vaccine developed by the UK’s Oxford University and AstraZeneca (NASDAQ: AZN) has an average efficacy of 70.4 percent, according to interim analysis announced today. In trials, the vaccine’s effectiveness varied depending on the dose amounts given. When two full doses were given a month apart the effectiveness stood at 62 percent, but this rose to 90 percent when the vaccine was given first as a half dose, and then as a full dose.
Administration (FDA) previously said vaccines would be required to be at least 50 percent effective to gain its approval.
With this latest round of trials complete, the team are preparing to submit the vaccine for regulatory approval. If approved, AstraZeneca hopes to to manufacture three billion doses of the vaccine to distribute worldwide. The Guardian reports a rollout could begin in weeks.